Protocol Ledger

NCT06046443 · Phase II · COMPLETED

A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity

Interventional Phase II clinical trial protocol NCT06046443 sponsored by Rhythm Pharmaceuticals in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-07-11 Enrollment: 28 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06046443
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)28 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06046443
Protocol FieldVerified Registry Value
NCT IdentifierNCT06046443
Consolidated Lead SponsorRhythm Pharmaceuticals
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment28 participants (ACTUAL)
Registered Start Date2024-07-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI